

1 **High prevalence of hepatitis B and HIV among women survivors of sexual violence in South Kivu**  
2 **province, eastern Democratic Republic of Congo**

3 **Hepatitis B and HIV among women survivors of sexual violence in South Kivu province**

4 Parvine Basimane Bisimwa<sup>1,2,3,4,5</sup>, Dieudonné Bihehe Masemo<sup>2,3</sup>, Aline Kusinza Byabene<sup>2,3</sup>, Georges  
5 Kikuni Besulani<sup>2,3</sup>, Théophile Kashosi Mitima<sup>4</sup>, Cadeau Mugisho Matabishi<sup>3</sup>, Bienfait Mitima Misuka<sup>4</sup>,  
6 Omari Mukanga<sup>6</sup>, Jean Paulin Mukonkole<sup>2,3</sup>, Jean Bisimwa Nachege<sup>7,8,9</sup>, Denis Mukwege<sup>2,5</sup>, Narcisse  
7 Patrice Joseph Komas<sup>1\*</sup>.

8 <sup>1</sup>Viral Hepatitis Laboratory, Institut Pasteur de Bangui, PO Box 923, Bangui, Central African Republic.

9 <sup>2</sup>Faculty of Medecine, Université Evangélique en Afrique (UEA), Bukavu, Democratic Republic of Congo

10 <sup>3</sup>Departments of Internal Medicine, Panzi Hôpital General Referral Hospital, Bukavu, Democratic  
11 Republic of Congo

12 <sup>4</sup>Molecular Biology Laboratory, Université Evangélique en Afrique (UEA), Bukavu, Democratic Republic  
13 of Congo

14 <sup>5</sup>International Center Advanced for Research and Training (ICART)/Panzi Fondation, Bukavu,  
15 Democratic Republic of Congo

16 <sup>6</sup>Statistical Service, VVS-Panzi General Referral Hospital, Bukavu, Democratic Republic of Congo

17 <sup>7</sup>Departments of Epidemiology, Infectious Diseases and Microbiology, University of Pittsburgh School of  
18 Public Health, Pittsburgh, PA, USA

19 <sup>8</sup>Departments of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public  
20 Health, Baltimore, MD, USA

21 <sup>9</sup>Department of Medicine, Stellenbosch University Faculty of Medicine and Health Sciences, Cape  
22 Town, South Africa

23 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

24 \*Corresponding author: [npkomas@yahoo.fr](mailto:npkomas@yahoo.fr) / [narcisse.komas@pasteur-bangui.cf](mailto:narcisse.komas@pasteur-bangui.cf) (NPJK)

## 26 Abstract

27 **Introduction:** Limited data are available on the prevalence rates of hepatitis B and acquired  
28 immunodeficiency syndrome (AIDS) among women survivors of sexual violence (WSSV) in South Kivu  
29 province, in the eastern part of the Democratic Republic of Congo (DRC), where armed conflicts persist.  
30 Here, we aimed to assess the prevalence of these two diseases in this vulnerable local population.

31 **Methods:** A total of 1002 WSSV, aged from 18 to 70 years old were enrolled from May 2018 to May  
32 2020 at three one-stop centers, set up at the Panzi, Mulamba and Bulenga hospitals. Blood samples  
33 were collected and tested for hepatitis B virus (HBV) and human immunodeficiency virus (HIV) antigens  
34 and antibodies using enzyme-linked immunoassay (ELISA) methods. Viral load quantification for HBV  
35 and HIV were performed using the GeneXpert.

36 **Results:** For HBV, overall prevalence was 8.9% (95% CI [7.2–10.8%]), 32.1% [29.3–35.0%], and 14.5%  
37 [12.3–16.8%] for HBsAg, anti-HBc and anti-HBs antibodies, respectively. Among the 89 HBsAg-positive  
38 patients, 17 (19.1%) were HBeAg-positive. The mean age was  $40.57 \pm 14.99$  years in the HBsAg-  
39 positive group ( $p=0.025$ ). Risk factors for HBV infection were age ( $\geq 35$  years) (AOR=1.83 [1.02-3.32];  
40  $p=0.041$ ), having no schooling (AOR=4.14 [1.35-12.62];  $p=0.012$ ) or only primary school-level  
41 (AOR=4.88 [1.61-14.75];  $p=0.005$ ), and multiple aggressors (AOR=1.76 [1.09-2.84],  $p=0.019$ ). The  
42 prevalence of HIV was 4.3% [3.1–5.7%]. HIV/HBV co-infection occurred only in 5 individuals (0.5%).  
43 The HBV viral load was detectable ( $>2,000$  copies/mL) in 61.8% of HBsAg-positive subjects and 64.8%  
44 HIV-positive subjects had a high viral load ( $>1,000$  copies/mL).

45 **Conclusion:** This study revealed a high prevalence of HBV and HIV infections among WSSV in South  
46 Kivu. These results highlight the urgent need for systematic screening of HBV and HIV by integrating  
47 fourth-generation ELISA tests in HIV and HBV control programs.

48 **Key words:** Survivors of sexual violence; HBV infection; HIV infection; HBV and HIV co-infection;  
49 South Kivu; Democratic Republic of Congo; DRC.

50

## 51 **Introduction**

52 Sexually transmitted infections (STIs) constitute a heavy public health burden in many developing  
53 countries, including the Democratic Republic of Congo (DRC). Two STIs, i.e. those caused by hepatitis  
54 B virus (HBV) and human immunodeficiency virus (HIV), affect approximately 2 billion and 37.7 million  
55 people worldwide, respectively [1,2]. HBV is one of the leading infectious killers globally, with 887,000  
56 deaths due to HBV-associated hepatic sequelae such as acute hepatitis, liver cirrhosis, and liver cancer  
57 or hepatocellular carcinoma (HCC), recorded worldwide in 2015 [1]. Its prevalence is highest in the  
58 Western Pacific and African regions, where respectively 6.2% and 6.1% of the adult population is  
59 infected [3]. The World Health Organization (WHO) has classified the DRC as an intermediate  
60 endemicity area, with 5 to 7.99% of HBV infection [1,3]. In endemicity areas, HBV infection is usually  
61 transmitted from mother to child at delivery or by horizontal transmission among children, especially  
62 during the first five years [3-5]. It is also transmitted by sexual intercourse through vaginal and seminal  
63 secretions, by tattooing and piercing with non-sterilized equipment, by blood exposure accidents, and by  
64 other infected body fluids such as saliva [1,3,4].

65 The Joint United Nations Program on HIV/AIDS (UNAIDS) and WHO reports show that among the 37.7  
66 million people living with HIV worldwide, adults (36.0 million) predominate. Of these infected adults,  
67 women, and girls (53%) were the most infected groups in 2020 [2,5,6]. According to the same reports,  
68 HIV infection was responsible for around 680,000 deaths worldwide in 2020, compared with 1.3 million  
69 in 2010 and 1.9 million in 2004, with a significant decrease (53%) in women and girls [2,6]. However,  
70 despite the decrease in HIV incidence and associated mortality worldwide with increased access to  
71 potent antiretroviral therapy, incidence rates can nonetheless be alarming in post- or armed conflict  
72 countries where sexual violence is used as weapon of war. In 2020, the WHO estimated that 30% of  
73 women have been raped, representing a vulnerable group that may be at high risk of HIV infection,  
74 particularly adolescent girls, and young women [6]. Sexual violence has become endemic in the eastern

75 DRC, particularly in South Kivu [7]. From September 1999 to March 2021, the teams from the Panzi  
76 Hospital have taken care of over 68,774 women survivors of sexual violence (WSSV), among whom  
77 only 12% were admitted in less than 72 h and 6% with pregnancies resulting from rape (Panzi  
78 Foundation Report 2021).

79 The South Kivu province, where this study was undertaken, is rife with frequent sexual violence  
80 perpetrated on women due to recurrent armed conflicts, especially in rural areas [7]. Furthermore,  
81 sporadic cases of sexual violence are reported in the city of Bukavu [8]. These situations may increase  
82 sexual transmission of HBV and HIV in this area due to their transmission mode. However, few studies  
83 have been conducted on the prevalence of HBV and HIV infections or the burden of HIV/HBV co-  
84 infection in South Kivu. This study aims to determine the prevalence of and the factors associated with  
85 HBV and HIV infections among WSSV enrolled at one-stop centers in South Kivu. This information is  
86 important for predicting the risk of HBV/HIV co-infection and for setting up suitable management of the  
87 infections.

## 88 **Methods**

### 89 **Study design, setting, and population**

90 This is a cross-sectional study conducted from May 2018 to May 2020. Participants were recruited from  
91 urban and rural one-stop centers of the Panzi Foundation, including the Panzi General Referral  
92 Hospital, the Mulamba Hospital Center, and the Bulenga Hospital Center. The Panzi Hospital is the  
93 reference center for the health sector in the city of Bukavu. This hospital specializes in several medical  
94 areas and today, it is a treatment center for victims and survivors of sexual violence. The hospital  
95 receives 5 to 7 female victims of sexual violence every day through the Panzi Foundation, within which  
96 the "one-stop center" model of care was developed by Prof [8]. Denis Mukwege, winner of the 2018  
97 Nobel Peace Prize. This model allows victims and survivors of sexual violence to receive holistic care  
98 (medical, psychosocial, legal, and socio-economic reintegration) and other services to restore their  
99 healthy life needs [8]. Panzi Hospital has partnered up with other one-stop centers, such as the

100 Mulamba Hospital Center, located at about 70 km southwest of Bukavu in the rural area of Walungu,  
101 and the Bulenga Hospital Center, located near Goma, 165 km from Bukavu.

## 102 **Eligibility criteria**

103 The study population included all women aged 18 years and over with a history of sexual violence of  
104 more than 3 months, who received treatment and medical care at one of the above-mentioned one-stop  
105 centers. They were admitted for management of various complications related to sexual violence  
106 including medical, surgical, gynecological, and social care. A total of 1002 women participants were  
107 included in this study. The sample size was determined based on HBV prevalence (5.0%) in the DRC  
108 [9], with a precision of  $\pm 3\%$  at a 95% confidence level.

## 109 **Specimen and data collection**

110 At each one-stop center, prior to administering a questionnaire, an information session was offered to  
111 WSSV providing clear explanations, in the local language where necessary, using readily  
112 understandable terms about HBV and HIV-related diseases. An informed-consent form was then signed  
113 by each participant and the collected information remained anonymous. Sociodemographic and clinical  
114 variables were recorded. Clinical variables mainly involved patient history of jaundice, vaccination,  
115 transfusion, scarification, tattoo, traditional excision, number of sex partners before and after sexual  
116 violence, number of aggressors, and the occurrence of pregnancy; sociodemographic variables included  
117 age, origin, tribe, level of schooling, religion, marital status, and occupation. Approximately 10 mL of  
118 venous blood was collected in an EDTA tube for rapid screening HIV and HBV tests and results were  
119 reported to participants immediately after screening. In addition, dried blood spots (DBS) were prepared  
120 in the Medical Research Laboratory (MRL) at the Université Evangélique en Afrique (UEA) in Bukavu by  
121 spotting a drop of whole blood on Whatman filter paper. This sample preparation was followed by drying  
122 and sealing the DBS in plastic bags for storage at room temperature in presence of a desiccant until  
123 transferred to the Viral Hepatitis Laboratory at the Institut Pasteur de Bangui in the Central African  
124 Republic (CAR) for further analysis.

## 125 **Serological assays**

126 The HBV markers were detected using an enzyme-linked immunosorbent assay (ELISA) provided in  
127 DiaSource kits (DiaSource ImmunoAssays S.A., Belgium) according to the manufacturer's instructions.  
128 All samples were tested for the hepatitis B surface antigen (HBsAg), and hepatitis B core antibody (anti-  
129 HBc). A confirmatory ELISA test of HBsAg was used for HBsAg-positive samples. HBsAg-negative  
130 samples were screened for the HBs antibody (anti-HBs Ab) and HBsAg-positive samples were screened  
131 for the hepatitis B e antigen/antibody (HBeAg/anti-HBe Ab) and anti-HBc IgM antibodies. The Murex  
132 ELISA kit, (DiaSorin S.p.A., Italy) was used for quality control and confirmation of all positive samples.  
133 The presence of HIV was detected using the HIV Ab/Ag Combo ELISA kit (DiaSource ImmunoAssays  
134 S.A.) according to the manufacturer's instructions. After serological testing, all HBV- and HIV-positive  
135 samples were transported to the Panzi Hospital laboratory for viral load quantification. This viral load  
136 detected HBV DNA and HIV RNA in the blood of patients using Cepheid GeneXpert kits Xpert® HBV  
137 Viral Load and Xpert® HIV-1 Qual for HBV and HIV, respectively by following the manufacturer's  
138 recommendations.

## 139 **Statistical analysis**

140 Data were collected from a structured survey questionnaire, compiled into a Microsoft Excel 2016  
141 spreadsheet, and then imported into Stata SE 14.0 (Stata Corp LP, College Station, Texas, USA) for  
142 clean-up and analysis.

143 To describe the data, we computed means and their standard deviations (SDs) and medians with  
144 interquartile ranges (IQRs) for continuous variables, as appropriate. Categorical variables were  
145 summarized as frequencies and their percentages. To compare two means or medians, we used  
146 Student's *t*-test. To compare proportions, we used the Pearson chi-square test or the Fisher exact test  
147 for proportions less than or equal to 5. We constructed univariate and multivariate logistic regression  
148 models to assess factors associated with HIV-positive and HBV-positive status among WSSV. Variables  
149 with a *p*-value 0.2 or lower were included in the model.

150 The adjusted odds-ratios (AOR) and their 95% confidence intervals (CI) were derived to measure the  
151 strength of the association between the variables. All  $p$ -values were two-sided, and  $p$ -values less than  
152 0.05 indicated statistical significance.

### 153 **Ethical approval and consent to participate**

154 This study obtained approval from the ethics committee of the Catholic University of Bukavu  
155 (UCB/CIE/NC/008/2016) reviewed in 2019 by the national health ethics committee  
156 (CNES001/DPSK/124PP/2019) and from the ethics and scientific committees of the University de  
157 Bangui (22/UB/FACSS/CSVPR/19). Written informed consent was signed by the participant in the  
158 interest of knowing her serological status to consider early treatment in case of a positive result, as well  
159 as for her participation in the study. The preliminary results for HBV and HIV screening were given to  
160 participants immediately after screening and 3 weeks later for definitive result. HIV- and HBV-positive  
161 cases were referred to the Panzi Hospital for medical care.

## 162 **Results**

### 163 **Sociodemographic and seroprevalence of HBV and HIV infection among survivors of sexual** 164 **violence**

165 The average age of the study participants was  $37.85 \pm 15.11$  years and most were 35 years old and  
166 older (53.9%). The majority were married (47.7%), Protestant (53.5%) and from rural areas (92.4%)  
167 (table 1). Of the 1002 participants, the prevalence rates of HBV markers were 8.9% (95% CI: [7.2 –  
168 10.8%]), 32.1% [29.3–35.0%], and 14.5% [12.3–16.8%] for HBsAg, anti-HBc and anti-HBs antibodies,  
169 respectively. Of the 89 HBsAg-positive participants, 17 (19.1%) were also HBeAg-positive.

170 The mean age was  $40.57 \pm 14.99$  years in the HB-positive group, statistically significantly higher than the  
171 overall mean age ( $p=0.025$ ). Furthermore, participants aged 35 years and older were more frequently  
172 HBsAg-positive than those under 35 years ( $p=0.027$ ). A statistical difference was observed in  
173 participants with no formal schooling or only or primary-school education (10.1 and 10.4%, respectively;



174  $p=0.017$ ) compared with those with secondary- or university-level education. However, there was no  
175 statistical difference in the prevalence of HBV infection according to marital status or occupation,  
176 despite the slightly higher number of infection cases among separated/divorced women and public  
177 sector workers (17.1 and 12.5%;  $p=0.064$  and  $p=0.922$ , respectively). Participants from the Havu tribe  
178 showed higher prevalence compared with participants from other tribes (19.1%;  $p<0.001$ ). Religion and  
179 geographic origin of participants were not statistically associated with HBsAg positivity.

180 Similarly, for the hepatitis B contact marker (anti-HBc), the 35+ age group had a high prevalence  
181 compared with the under-35 age group (37.8% vs. 25.5%;  $p<0.001$ ). For anti-HBs antibodies, a  
182 statistical difference was also observed between the age groups, with higher immunization in the over-  
183 35 age group (17.4% vs. 11.1%;  $p=0.007$ ) compared with those under 35 years of age.

184 A total of 43 of the 1002 participants (4.3% [3.1%–5.7%]) tested positive for HIV. The Fuliru tribe was  
185 more frequently associated with HIV infection than the other tribes (12.2%;  $p=0.018$ ). Although HIV  
186 infection appeared high, it was not statistically significant among women aged 35 years and over  
187 (4.4%), with no schooling (4.9%), married (5.2%), public sector workers (12.5%), Catholic (5.1%), or  
188 from rural areas (4.4%) (Table 1). Regarding HBV-HIV co-infection, the prevalence was 0.5%.

189

190 Table 1. Sociodemographic characteristics and prevalence of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) among survivors of sexual  
 191 violence in South Kivu

Characteristics	Number	%	HBsAg			Anti-HBc antibodies			Anti-HBs antibodies			HIV Ag/Ab		
			Positive (n)	%	<i>p</i>	Positive (n)	%	<i>p</i>	Positive (n)	%	<i>p</i>	Positive (n)	%	<i>p</i>
<b>Overall prevalence</b>	1002	100	89(1002)	8.9		322(1002)	32.1		132(913)	14.5		43(1002)	4.3	
<b>Age (years)</b>														
<35	462	46.1	31(462)	6.7	0.027	118(462)	25.5	<0.001	48(431)	11.1	0.007	20(462)	4.3	0.957
≥35	540	53.9	58(540)	10.7		204(540)	37.8		84(482)	17.4		23(540)	4.4	
<b>Schooling level</b>														
No schooling	616	61.5	62(616)	10.1	0.017	218(616)	35.4	<0.001	84(554)	15.2	0.593	30(616)	4.9	0.587
Primary	221	22.1	23(221)	10.4		71(221)	32.1		30(198)	15.2		6(221)	2.7	
Secondary	163	16.3	4(163)	2.5		31(163)	19.0		18(159)	11.3		7(163)	4.3	
University	2	0.2	0(2)	0.0		2(2)	100.0		0(2)	0.0		0(2)	0.0	
<b>Marital status</b>														
Single	235	23.5	17(235)	7.2	0.064	56(235)	23.8	0.015	24(218)	11.0	0.353	7(235)	3.0	0.507
Married	519	51.8	44(519)	8.5		183(519)	35.3		75(475)	15.8		27(519)	5.2	
Separated/Divorced	76	7.6	13(76)	17.1		28(76)	36.8		11(63)	17.5		3(76)	3.9	
Widowed	172	17.2	15(172)	8.7		55(172)	32.0		22(157)	14.0		6(172)	3.5	
<b>Occupation</b>														
No occupation	174	17.4	13(174)	7.5	0.922	55(174)	31.6	0.706	29(161)	18.0		6(174)	3.4	0.537

Farmer	667	66.6	60(667)	9.0		222(667)	33.3		88(607)	14.5		32(667)	4.8	
School /Pupil/ Student	105	10.5	11(105)	10.5		28(105)	26.7		9(94)	9.6	0.323	3(105)	2.9	
Entrepreneur (trade)	48	4.8	4(48)	8.3		14(48)	29.2		6(44)	13.6		1(48)	2.1	
Public sector worker	8	0.8	1(8)	12.5		3(8)	37.5		0(7)	0.0		1(8)	12.5	
<b>Tribe</b>														
Shi	478	47.7	28(478)	5.8	<0.001	127(478)	26.6	0.009	61(450)	13.4		19(478)	4.0	0.018
Havu	184	18.4	35(184)	19.0		82(184)	44.6		23(149)	15.4		5(184)	2.7	
Fuliru	82	8.2	7(82)	8.5		28(82)	34.1		9(75)	12.0		10(82)	12.2	
Lega	74	7.4	7(74)	9.4		24(74)	32.4		7(67)	10.4	0.680	4(74)	5.4	
Bembe	45	4.5	2(45)	4.4		18(45)	40.0		10(43)	23.3		1(45)	2.2	
Tembo	54	5.4	5(54)	9.3		16(54)	29.6		7(49)	14.3		1(54)	1.9	
Other	85	8.5	5(85)	5.9		27(85)	31.8		15(80)	18.7		3(85)	3.5	
<b>Religion</b>														
No religion	7	0.7	1(7)	14.3	0.071	4(7)	57.1	0.379	1(6)	16.7	0.703	0(7)	0.0	0.632
Catholic	429	42.8	40(429)	9.4		139(429)	32.4		57(389)	14.7		22(429)	5.1	
Muslim	5	0.5	2(5)	40.0		3(5)	60.0		0(3)	0.0		0(5)	0.0	
Protestant	536	53.5	42(536)	7.8		167(536)	31.2		73(494)	14.8		21(536)	3.9	
Other	25	2.5	4(25)	16.0		9(25)	36.0		1(21)	4.8		0(25)	0.0	
<b>Geographic area</b>														
Rural	926	92.4	79(926)	8.5	0.173	296(926)	32.0	0.687	120(847)	14.2	0.365	41(926)	4.4	0.458
Urban	76	7.6	10(76)	13.2		26(76)	34.2		12(66)	18.2		2(76)	2.6	

192 *Ab, antibodies; Ag, antigens; HBs Ag, hepatitis B surface antigens; HBc, hepatitis B core*

193 **Clinical history, and HBV and HIV infections among survivors of sexual violence**

194 For HBV infection, a statistically significant association was found between the presence of HBsAg and multiple aggressors (11.0%;  $p=0.022$ ). The absence of  
195 HBV vaccination was statistically associated with the presence of HBsAg ( $p=0.011$ ). There was no statistical difference between the prevalence of HBV infection  
196 and other factors. However, participants with a history of tattoo, traditional genital excision, multiple sexual partners before sexual violence and current multiple  
197 sexual partners had slightly higher prevalences of HBV (10.3%, 10.6%, 10.0%, and 9.1%, respectively) (Table 2).

198 For HIV infection, no association was found with those factors.

199

201 Table 2. Clinical history and hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections among women survivors of sexual violence

Characteristics	Number	HBsAg			HIV Ag/Ab		
		N(%)	Positive n(%)	Negative n(%)	p	Positive n(%)	Negative n(%)
<b>Pregnancy</b>							
Yes	61(6.1)	5(8.2)	56(91.8)	0.846	2(3.3)	59(96.7)	0.687
No	941(93.9)	84(8.9)	857(91.1)		41(4.4)	900(95.6)	
<b>History of jaundice</b>							
Yes	23(2.3)	2(8.7)	21(91.3)	0.975	1(4.3)	22(95.7)	0.989
No	979(97.7)	87(8.9)	892(91.1)		42(4.3)	937(95.7)	
<b>Vaccination</b>							
Yes	6(0.6)	0(0.0)	6(100.0)	0.011	0(0.0)	6(100.0)	0.603
No	996(99.4)	89(8.9)	907(91.1)		43(4.3)	953(95.7)	
<b>Transfusion</b>							
Yes	47(4.7)	1(2.1)	46(97.9)	0.095	1(2.1)	46(97.9)	0.453
No	955(95.3)	88(9.2)	867(90.8)		42(4.4)	913(95.6)	
<b>Condom use</b>							
Never	974(97.2)	88(9.0)	886(91.0)	0.316	41(4.2)	933(95.8)	0.450
Yes	28(2.0)	1(3.5)	27(96.5)		2(7.1)	26(92.9)	
<b>Tattoo</b>							

Yes	39(3.9)	4(10.3)	35(89.7)	0.758	2(5.1)	37(94.9)	0.793
No	963(96.1)	85(8.8)	878(91.2)		41(4.3)	922(95.7)	
<b>Scarification</b>							
Yes	28(2.8)	2 (7.1)	26(92.9)	0.743	0(0.0)	28(100.0)	0.256
No	974(97.2)	87(8.9)	887(91.1)		43(4.4)	931(95.6)	
<b>Traditional excision</b>							
Yes	123(12.3)	13(10.6)	110(89.4)	0.483	4(3.3)	119(96.7)	0.544
No	879(87.7)	76(8.6)	803(91.4)		39(4.4)	840(95.6)	
<b>Multiple sex partners before sexual violence</b>							
Yes	609(60.8)	61(10.0)	548(90.0)	0.174	28(4.6)	581(95.4)	0.633
No	393(39.2)	28(7.1)	365(92.9)		15(3.8)	378(96.2)	
<b>Current multiple sex partners</b>							
Yes	536(53.5)	49(9.1)	487(90.9)	0.824	20(3.7)	516(96.3)	0.354
No	466(46.5)	40(8.6)	426(91.4)		23(4.9)	443(95.1)	
<b>Number of aggressors</b>							
Single	521(52.0)	36(6.9)	428(93.1)	0.022	21(4.0)	499(96.0)	0.672
Multiple	481(48.0)	53(11.0)	428(89.0)		22(4.6)	459(95.4)	

202 Ab, antibodies; Ag, antigens; HBs Ag, hepatitis B surface antigens; HBc, hepatitis B core; virus; HIV, human immunodeficiency virus.

203 **Risk factors and HBV infection**

204 The results showed that HBs-positive status was associated with women aged 35 or older (AOR=1.83  
 205 [1.02–3.32];  $p=0.041$ ), having no schooling (AOR=4.14 [1.35–12.62];  $p=0.012$ ) or primary schooling only  
 206 (AOR=4.88 [1.61–14.75];  $p=0.005$ ), being part of the Havu tribe (AOR=4.84 [1.08–21.64];  $p=0.039$ ),  
 207 and multiple aggressors (AOR=1.76 [1.09–2.84];  $p=0.019$ ) (Table 3).

208 For HIV, after adjustment of the logistic regression model, we did not find any statistically significant  
 209 associations between the risk factors studied and HIV status among WSSV ( $p>0.05$ ).

210

211 Table 3. Univariate and multivariate analysis of factors associated with hepatitis B status among  
 212 survivors of sexual violence

Characteristics	COR [95% CI]	p-Value	AOR [95% CI]	p-value
<b>Age group (years)</b>				
<35	1 (reference)		1 (reference)	
≥35	1.67 [1.06–2.63]	0.027	1.83 [1.02–3.32]	0.041
<b>Marital status</b>				
Single	1 [reference]		1 [reference]	
Married/Homemaker	1.18 [0.66–2.12]	0.562	0.93 [0.47–1.85]	0.848
Separated/Divorced	2.64 [1.21–5.74]	0.014	2.15 [0.84–5.47]	0.107
Widowed	1.22 [0.59–2.52]	0.582	0.74 [0.28–1.96]	0.547
<b>Schooling level</b>				
None	4.44 [1.59–12.41]	0.004	4.14 [1.35–12.62]	0.012
Primary	4.61 [1.56–13.62]	0.006	4.88 [1.61–14.75]	0.005
Secondary	-	-	-	-
University	1 (reference)		1 (reference)	
<b>Religion</b>				
None	1 (reference)			
Catholic	0.61 [0.07–5.25]	0.659	-	-
Muslim	4.00 [0.25–63.95]	0.327	-	-



Protestant	0.51 [0.59–4.33]	0.538	–	–
Other	1.14 [0.10–12.24]	0.912	–	–
<b>Blood transfusion</b>				
No	1 (reference)		1 (reference)	
Yes	0.21 [0.29–1.57]	0.130	0.19 [0.02–1.45]	0.110
<b>Aggressors</b>				
Single	1 (reference)		1 (reference)	
Multiple	1.66 [1.07–2.59]	0.023	1.76 [1.09–2.84]	0.019
<b>Tribe</b>				
Bembe	1 (reference)		1 (reference)	
Fuliru	2 [0.39–10.09]	0.398	2.25 [0.43–11.70]	0.334
Havu	5.05 [1.16–21.85]	0.030	4.84 [1.08–21.64]	0.039
Lega	2.24 [0.44–11.32]	0.327	2.68 [0.51–14.03]	0.241
Shi	1.33 [0.30–5.80]	0.698	1.42 [0.31–6.34]	0.642
Tembo	2.19 [0.40–11.89]	0.362	2.89 [0.51–16.32]	0.228
Other	1.34 [0.25–7.21]	0.731	1.56 [0.28–8.72]	0.609
<b>Use of condoms</b>				
Yes	1 (reference)		1 (reference)	
No	2.68 [0.36–19.97]	0.336	1.84 [0.22–14.75]	0.565

213 \*COR: Crude odds ratio; \*\*AOR: Adjusted odds ratio. In this table, we present the crude and adjusted  
 214 odds ratios.

215

## 216 Level of HBV and HIV viral loads in positive participants

217 Out of a total of 89 HBsAg-positive samples, the mean viral load was  $4949423.89 \pm 22250009$  IU/mL;  
 218 38.2% of the samples had an undetectable viral load, 39.3% a low viral load ( $<2000$  IU/mL), and 22.5%  
 219 a high viral load ( $\geq 2000$  IU/mL). For HIV, for those participants who tested positive for the first time, the  
 220 average viral load was  $227924.24 \pm 734065.81$  copies/mL (table 4). The distribution of the HIV viral load

221 showed a low (<1000 copies/mL) viral load for 35.2% of the patients and a high (≥1000 copies/ml) for  
222 64.8% (Table 4).

223 Table 4. HBV and HIV viral load results in participants who tested positive

<b>Virological parameters</b>	<b>Number</b>	<b>%</b>
<b>HBV DNA viral load (UI/mL)</b>	<b>N=89</b>	
Mean±SD	4949423.89 ± 22250009	
Undetectable	34	38.2
< 2000	35	39.3
≥ 2000	20	22.5
<b>HIV RNA viral load (copies/mL)</b>	<b>N=34</b>	
Mean±SD	227924.24 ± 734065.81	
< 1000	12	35.2
≥ 1000	22	64.8

224

## 225 **Discussion**

226 In this study, the overall prevalence of HBsAg was 8.9% [7.2%-10.8%] and 32.1% [29.3%–35.0%] for  
227 anti-HBc antibody. These results demonstrate the high burden of HBV in this vulnerable population. The  
228 prevalence of HBV infection varies across regions and different types of population in the DRC [9].  
229 Previous studies on HBV infection have focused on blood donors in DRC different regions, reporting  
230 HBsAg prevalence rates ranging from 6.8% to 9.2%, but in other population groups, prevalence seems  
231 to be much lower [10-17]. For example, one study in the Maniema province reported a prevalence of  
232 5.9% for HBsAg in pregnant women [18]. But the results of 2013-2014 Demographic and Health Survey  
233 on the general population showed a prevalence of 3.3% in adults and 2.2% in children [9]. In contrast,  
234 an HBsAg prevalence of 24.6% was reported on samples from 2003 to 2012 in the yellow fever  
235 surveillance program from patients with acute febrile jaundice and suspected yellow fever [19].

236

237 The difference in hepatitis B prevalence rates in these different regions of the DRC can likely be  
238 attributed to the exposure to different risk factors according to population type, and probably arises from  
239 the absence of a viral hepatitis control and prevention program, as well as the fact that hepatitis B  
240 vaccination is limited to infants only. This variation in prevalence is also found in sub-Saharan Africa,  
241 where the rate of HBV infection, which is often very high, also varies with the country, the studied  
242 populations, and the used techniques [20-37]. For example, the overall prevalence of 42.3% for anti-  
243 HBc antibody with 15.5% for HBsAg in students with high sexual activity in Bangui [23].

244 Our investigation also revealed that 14.5% of the study population shows anti-HBs antibodies. Of the  
245 participants with this immunization marker, only 11.4% had a history of hepatitis B vaccination when  
246 tested within 72 h of sexual violence, and 88.6% had no history of previous hepatitis B vaccination. In  
247 the latter, the total anti-HBc antibody was present, clearly demonstrating that they had been in contact  
248 with the virus itself. An association was found between the rate of immunization against HBV infection  
249 and the over-35 years age group. Therefore, it is difficult to demonstrate precisely when the infection  
250 was acquired with respect to sexual abuse but given the high proportion of antibody detection in older  
251 patients, the hypothesis of infection acquired in conjunction with sexual abuse is highly plausible.  
252 Unfortunately, the antibody titer was not determined in this study. The anti-HBs antibody titer for HBV  
253 has been shown to decrease with age according to the age of the infection. Thus, the proportion of older  
254 individuals with anti-HBs antibodies at  $\geq 10$  IU/mL may be low if the infection was acquired in childhood,  
255 although they may nevertheless remain immunized against the infection [38].

256

257 For HIV infection, a prevalence of 4.3% [3.1%–5.7%] was found using fourth-generation ELISA tests.  
258 This prevalence is very high for this population category compared to that reported in a previous study  
259 among blood donors in Bukavu, which showed a low prevalence using rapid tests [11]. However, before  
260 the introduction of blood safety protocols in Kisangani, a prevalence of 4.7% was reported in this same

261 group [15]. Nevertheless, our study demonstrates, the high prevalence of HIV among sexually abused  
262 patients in South Kivu province.

263

264 The link between sexual violence against women and girls and HIV acquisition has been shown in  
265 several studies [39]. For example, in Uganda, 15–49 year-old women who had experienced sexual  
266 violence showed a 1.55 risk of HIV infection compared with those who had never experienced violence  
267 [40]. Similarly, in a study in South Africa, young women aged 15–24 years who reported multiple  
268 episodes of sexual violence were 1.51 more at risk to acquire HIV than women with one or no episodes  
269 of sexual violence; furthermore, an estimated 12% of new HIV infections could be attributed to sexual  
270 violence [41].

271

272 The same findings were reported in a cross-sectional study of 28,000 married women aged 15–49 years  
273 in India, with a 4-fold higher risk of being HIV-positive among those who had experienced physical and  
274 sexual violence by their partners than those who had not [42]. Although studies of HIV among women  
275 who have experienced sexual violence are rare in the DRC, HIV prevalence is often very high (7.5%)  
276 among female sex workers. This high prevalence contrasts with the overall HIV incidence in the general  
277 population, which is estimated to have decreased from 2010 to 2020 from 1.2% to 0.7%, with a national  
278 prevalence of 1.1% among women aged 15–49 years [43]. Furthermore, prevalence may be  
279 underestimated considering the low rate of HIV testing in different groups and key populations, the use  
280 of rapid tests in routine screening, and diagnoses that sometimes produce false negatives with a risk of  
281 undetected HIV cases [44]. It has been well documented that women are two to four times more likely  
282 than men to contract the virus through unprotected vaginal penetration [45-47]. Sexual abuse of women  
283 and girls by one or more individuals is a direct risk factor for HIV transmission. The risk factors  
284 associated with HIV infection observed in this study were as follows: age less than or equal to 25 years,  
285 belonging to the Fulero tribe, occasional condom use, and number of assailants greater than or equal to

286 5. Women with a history of sexual assaults with more than 5 men in their lifetime had a higher frequency  
287 of HIV infection than those with fewer than 5 abusers. These results are consistent with studies that  
288 have shown that HIV is more prevalent among young women, sex workers, those with multiple sexual  
289 partners, those who have experienced physical or sexual violence, and those with low levels of  
290 education, but other factors such as poverty and early marriage are also implicated [47-50].

291  
292 The main sources of HIV transmission vary by country. Risks found in sexual behavior include age at  
293 first intercourse [51], being sexually active, having multiple sexual partners, having unprotected sex,  
294 having unprotected sex with strangers [52], having sex during or after alcohol use [53], sexual violence  
295 [45], and transactional sex [54].

296  
297 Addressing violence against women and gender equality has been identified by UNAIDS in the AIDS  
298 Investment Framework as essential for an effective response to the HIV epidemic [55]. Addressing  
299 gender-based violence (GBV) could have a significant impact on the HIV epidemic. Indeed, the national  
300 HIV program needs to recognize the following aspects: the direct and indirect implications of GBV in the  
301 mechanism of HIV dissemination, the importance of perpetrator dynamics, and that GBV reduction  
302 should be part of HIV prevention programs. Effective interventions are likely to include a structural  
303 component and a sexual violence awareness component.

304  
305 Our study also revealed the prevalence of HBV/HIV co-infection that was 0.5%. This prevalence  
306 appears to be low, because most studies on co-infection in sub-Saharan Africa always report high  
307 prevalence rates [56]. Nevertheless, this prevalence varies across regions defined by HBV endemicity.  
308 In regions such as sub-Saharan Africa and East Asia, where HBV prevalence is high, most HBV  
309 infections occur perinatally or in early childhood through close household contact, medical procedures,  
310 or cultural practices such as scarification or tattooing [57]. HBV infections are therefore more likely to

311 progress to chronic infections, resulting in a high prevalence of chronic HBV infection among young  
312 people at risk for sexual HIV [58].

313

314 HBV and HIV quantifications were performed on samples from our study populations using the  
315 automated GeneXpert® system. The HBV viral load results showed that 77.5% had undetectable or low  
316 viral load and 22.5% had a high viral load ( $\geq 2000$  IU/mL). The 77.5% for whom the viral load was  
317 undetectable or low were not likely to be put on antiviral therapy. However, the 22.5% with high viral  
318 load should be treated therapeutically for infection, following further testing. This quantification test must  
319 be made available and accessible to all patients in South Kivu to avoid shortages of antivirals or high  
320 expenses related to the routine therapeutic management of anyone infected with HBV. Indeed, it is  
321 known that more than 90% of infected adults spontaneously recover from acute viral hepatitis B, with  
322 the disappearance of HBsAg after about 6 months [59,60]. Accurate measurement of HBV DNA levels  
323 in the blood is essential to diagnose HBV infection, establish the prognosis of HBV-related liver disease,  
324 and guide therapeutic decision-making to determine whether to initiate antiviral therapy and monitor the  
325 virological response to antiviral therapy and emergence of resistance [61,62].

326

327 In resource-limited countries such as the DRC, the ability to determine the HBV viral load is a major  
328 issue for the therapeutic management of patients, because the technical facilities recommended by  
329 international guidelines are not available and/or accessible [63]. Quantifying HBV DNA in the blood is  
330 one of the essential tests to establish the prognosis of infection and support any therapeutic decisions  
331 [61,62].

332 For the 34 subjects in whom the HIV viral load was determined, 64.8% had a high viral load ( $\geq 1000$   
333 copies/mL) and 35.2% a low viral load ( $< 1000$  copies/mL). These viral loads show that HIV testing is still  
334 a real problem in this area of the world due to the inaccessibility of ELISA tests, which clearly have  
335 added value for the detection and diagnosis of HIV cases. The dearth of modern technical facilities

336 contributes to the underestimation of HIV cases following the use of rapid tests. In this study, the  
337 positive cases had a detectable HIV viral load, except for nine cases that were not tested due to the  
338 insufficient amount of blood sample.

339 Our results clearly show the importance of using comprehensive tests for diagnosis of HBV and HIV in a  
340 vulnerable population group. However, not all tests to establish a complete diagnosis of liver diseases,  
341 such as transaminase and other complementary tests, were carried out, which thus constitutes a  
342 limitation of this study. Determining viral load remains an essential tool for the management of HBV  
343 infection.

344

### 345 **Conclusion**

346 This study shows a high prevalence of HBV and HIV infections among girls and women who have  
347 survived sexual violence in South Kivu, despite the low national prevalence of HIV and the intermediate  
348 endemicity of HBV infection in the DRC. In this study, the ELISA technique revealed that the prevalence  
349 of these infections is underestimated in South Kivu where girls and women have been exposed to  
350 sexual violence for many years due to repetitive wars. We suggest that actions to combat sexual  
351 violence against girls and women be integrated into strategies to combat HIV/AIDS and viral hepatitis B.

352

### 353 **Contributors**

354 JBN and NPJK supervised the study. PBB, JBN, and NPJK designed the study, wrote the first  
355 manuscript. PBB, TKM, CMM, and BMM contributed to the laboratory analyses. PBB and OM performed  
356 the statistical analyses. PBB, DBM, AKB, GKB and CMM contributed to the collection of clinical data  
357 and the medical management of patients. PBB, JNB, NPJK, JPM, DMM contributed to the critical  
358 revision of the manuscript. All authors contributed to the interpretation of the results, approved the final  
359 manuscript and accept responsibility for the decision to submit it for publication.

360

361 **Funding**

362 World Bank, grant number IDA H 980-ZR

363

364 **Declaration of interests**

365 The authors declare that they have no competing interests.

366

367 **Data Sharing**

368 All data were encoded and stored in an electronic database. Follow-up sheets were securely stored at  
369 the ICART/Panzi Foundation Research Center and accessible only to the principal investigator of the  
370 study. These data include epidemiological, clinical and therapeutic data. As these data are anonymized  
371 for the protection of participants according to the health ethics guidelines of our region, we cannot make  
372 them available to third parties.

373

374 **Acknowledgements**

375 The research presented in this publication was funded by the World Bank through the Panzi Foundation.  
376 We would like to thank the viral hepatitis laboratory team at the Institut Pasteur de Bangui for all the  
377 support received in conducting the laboratory analyses and facilitating the technical operations. This  
378 work is a research collaboration between the Panzi Foundation and the Institut Pasteur de Bangui. We  
379 are very grateful for the involvement of the director of the three 'One Stop Center' hospital. We would  
380 also like to thank Mr Giscard Wilfried Koyaweda, Mr Rodrigue Balthazar Basengere Ayagirwe, Mr Ahadi  
381 Bwihangane Birindwa, Mr Patrick Ntagereka Bisimwa for their contribution in the re-reading of this  
382 manuscript.

383

384 **References**



- 385 1. WHO. Global hepatitis report, 2017. Geneva: World Health Organization, 2017.  
386 (<https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/> , accessed July 21, 2021).
- 387 2. UNAIDS 2021 Global HIV & AIDS statistics (<https://www.unaids.org/en/resources/fact-sheet> ,  
388 accessed Dec 21, 2021).
- 389 3. World Health Organization. Combating hepatitis B and C to reach elimination by 2030. Geneva:  
390 WHO, 2016.
- 391 4. World Health Organization. Global health sector strategy on viral hepatitis 2017–2021. Geneva:  
392 WHO; 2017. Available from: <http://www.who.int/hepatitis/strategy2016-2021/ghss-hep>
- 393 5. World Health Organization. Global progress report on HIV, viral hepatitis and sexually  
394 transmitted infections, 2021 Accountability for the global health sector strategies 2016–2021: actions for  
395 impact. Available at: <https://www.who.int/publications/i/item/9789240027077>.
- 396 6. UNAIDS Global AIDS Update 2021— Confronting inequalities  
397 (<http://lawsandpolicies.unaids.org/> accessed Dec 21, 2021).
- 398 7. Mukwege DM, Nangini C. Rape with extreme violence: the new pathology in South Kivu,  
399 Democratic Republic of Congo. PLoS Med. 2009 Dec;6(12):e1000204. doi:  
400 10.1371/journal.pmed.1000204.
- 401 8. Mukwege D, Berg M. A Holistic, Person-Centred Care Model for Victims of Sexual Violence in  
402 Democratic Republic of Congo: The Panzi Hospital One-Stop Centre Model of Care. PLoS Med. 2016;  
403 13(10): e1002156. doi:10.1371/journal.pmed.1002156.
- 404 9. Thompson P, Parr JB, Holzmayer V, Carrel M, Tshetu A, Mwandagirwa K, et al.  
405 Seroepidemiology of Hepatitis B in the Democratic Republic of the Congo. Am J Trop Med Hyg. 2019  
406 Jul;101(1):226-229. doi: 10.4269/ajtmh.18-0883
- 407 10. Kabamba NM, and Kabyla IB. Prévalence des marqueurs infectieux chez les donneurs de sang  
408 en milieu rural. Cas de l'Hôpital General de Reference de Kamina]. Santé Publique. 2013; 25, 213-217

- 409 11. Namululi BA, Guerrieri C. and Dramaix M. Impact of Method of Re-  
410 on the Prevalence of HIV and HBV in Bukavu, DR Congo. *Medicine et Santé Tropicales*. 2012; 1, 69-74.
- 411 12. Kabinda JM, Miyanga SA, Misingi P, Ramarani SY. Les hépatites B et C chez les donneurs  
412 bénévoles de sang et non rémunérés à l'Est de la République Démocratique du Congo. *Transfusion*  
413 *Clinique et Biologique*. 2014 ; 21, 111-115. <https://doi.org/10.1016/j.tracli.2014.04.001>
- 414 13. Kabemba B, Kasendue E, Shiku M, Mukena T, Kasolva T, Kabingie N, et al. Seroprevalence of  
415 Hepatitis B Virus Infection (HBsAg) in Rural Blood Donors, Moba, Tanganyika Province, Democratic  
416 Republic of Congo (2014 to 2016). *Open Access Library Journal*. 2017; 4, 1-5. doi:  
417 10.4236/oalib.1103434.
- 418 14. Michel KN and Benjamin IK. Prévalence des marqueurs infectieux chez les donneurs de sang  
419 en milieu rural. Cas de l'hôpital général de référence de Ka mina. *Santé Publique*. 2013 ; 25, 213-217.
- 420 15. Batina A, Kabemba S and Malengela R. Infectious Markers among Blood Donors in Democratic  
421 Republic of Congo. *Revue Médicale de Bruxelles*. 2007; 28, 145-149.
- 422 16. Kakisingi NC, Mukuku O, Matanda KS, Manika MM, Kyabu KV, Kasamba IE, et al. Profil  
423 épidémiologique et séroprévalence des donneurs de sang aux cliniques universitaires de Lubumbashi,  
424 République Démocratique du Congo. *Pan African Medical Journal*. 2016 ; 23, 175.
- 425 17. Mbendi NC, Longo-Mbenza B, Mbendi NS, Muyembe Tamfumu JJ, Situa KH and Vangu ND.  
426 Prévalence du VIH et de l'Antigène HBS chez les donneurs du sang, risque résiduel de contamination  
427 chez les receveurs du sang de Kinshasa-Est, République Démocratique du Congo. *Médecine Tropicale*.  
428 2001; 61, 139-1423
- 429 18. Kabinda J, Akilimali T, Miyanga A, Donnen P et Michèle D. Hepatitis B, Hepatitis C and HIV in  
430 Pregnant Women in the Community in the Democratic Republic of Congo. *World Journal of AIDS*. 2015;  
431 5, 124-130. doi: 10.4236/wja.2015.52015,
- 432 19. Makiala-Mandanda S et al. High prevalence and diversity of hepatitis viruses in suspected  
433 cases of yellow fever in the Democratic Republic of Congo. *J Clin Microbiol*. 2017 ; 55:1299–1312.

- 434 20. Amponsah-Dacosta E. Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan  
435 Africa: Implications for elimination of viral hepatitis by 2030?. *World J Gastroenterol.* 2021;27(36):6025-  
436 6038. doi:10.3748/wjg.v27.i36.6025
- 437 21. Kafeero HM, Ndagire D, Ocamo P, Kudamba A, Walusansa A, Sendagire H. Prevalence and  
438 predictors of hepatitis B virus (HBV) infection in east Africa: evidence from a systematic review and  
439 meta-analysis of epidemiological studies published from 2005 to 2020. *Arch Public Health.* 2021 Sep  
440 18;79(1):167. doi: 10.1186/s13690-021-00686-1
- 441 22. Komas NP, Vickos U, Hübschen JM, Béré A, Manirakiza A, Muller CP, Le Faou A. Cross-  
442 sectional study of hepatitis B virus infection in rural communities, Central African Republic. *BMC Infect*  
443 *Dis.* 2013;13:286 doi: 10.1186/1471-2334-13-286
- 444 23. Komas NP, Bai-Sepou S, Manirakiza A, Léal J, Béré A, Le Faou A. The prevalence of hepatitis  
445 B virus markers in a cohort of students in Bangui, Central African Republic. *BMC Infect Dis.* 2010 Jul  
446 29;10:226. doi: 10.1186/1471-2334-10-226.
- 447 24. Akinbami AA, Oshinaike OO, Dosunmu OA, Adeyemo TA, Adediran A, Akanmu S, et al.  
448 Seroprevalence of hepatitis B e antigen (HBe antigen) and B core antibodies (IgG anti-HBcore and IgM  
449 anti-HBcore) among hepatitis B surface antigen positive blood donors at a Tertiary Centre in Nigeria.  
450 *BMC Res Notes.* 2012 Mar 28;5:167. doi: 10.1186/1756-0500-5-167.
- 451 25. Tsague MK, Fotio AL, Bomgning CLK, Nguéfack-Tsague G, Fopa F, Nguélefack TB.  
452 Prevalence of viral and non-viral hepatitis in Menoua Division, West Region, Cameroon: a retrospective  
453 hospital-based study. *Pan Afr Med J.* 2019 Apr 29; 32:212. doi: 10.11604/pamj.2019.32.212.16495.
- 454 26. Bigna JJ, Amougou MA, Asangbeh SL, Kenne AM, Noumegni SRN, Ngo-Malabo ET, Noubiap  
455 JJ. Seroprevalence of hepatitis B virus infection in Cameroon: a systematic review and meta-analysis.  
456 *BMJ Open.* 2017 Jun 30;7(6):e015298. doi: 10.1136/bmjopen-2016-015298
- 457 27. Xie, D.-D., Li, J., Chen, J.-T., Eyi, U.M., Matesa, R.A., Obono, M.M.O., et al. Seroprevalence of  
458 Human Immunodeficiency Virus, Hepatitis B Virus, Hepatitis C Virus, and *Treponema pallidum*

- 459 Infections among Blood Donors on Bioko Island, Equatorial Guinea. PLoS ONE. 2015;10,  
460 e0139947.<https://doi.org/10.1371/journal.pone.0139947>
- 461 28. Mongo-Onkouo A, Itoko OR, Boumba A, Niama F, Ahoui-Apendi C, Mimiesse MJ et al.  
462 Seroprevalence and Molecular Biodiversity of Hepatitis B and Delta Virus Infections in the Republic of  
463 Congo. Open Journal of Gastroenterology. 2018; 8, 448-454. doi: 10.4236/ojgas.2018.812046
- 464 29. Baseke J, Musenero M, Mayanja-Kizza H. Prevalence of hepatitis B and C and relationship to  
465 liver damage in HIV infected patients attending Joint Clinical Research Centre Clinic (JCRC), Kampala,  
466 Uganda. Afr Health Sci. 2015 Jun;15(2):322-7. doi: 10.4314/ahs.v15i2.3
- 467 30. Lakoh S, García-Tardón N, Adekanmbi O, van der Valk M, Smith SJ, Grobusch MP. Prevalence  
468 of viral hepatitis B and C in Sierra Leone-current knowledge and knowledge gaps: a narrative review.  
469 Trans R Soc Trop Med Hyg. 2021 Oct 1;115(10):1106-1113. doi: 10.1093/trstmh/tra054.
- 470 31. Musa OL, B. M. Bussell S, Borodo MM, Samaila AA. Prevalence of hepatitis B virus infection in  
471 Nigeria, 2000-2013: a systematic review and meta-analysis. Niger J Clin Pract. 2015;18(2):163–172.  
472 doi: 10.4103/1119-3077.151035;
- 473 32. Ofori-Asenso R, Agyeman AA. Hepatitis B in Ghana: a systematic review & meta-analysis of  
474 prevalence studies (1995–2015) BMC Infect Dis. 2016;16(1):130. doi: 10.1186/s12879-016-1467-5.;
- 475 33. Lingani M, et al. High prevalence of hepatitis B infections in Burkina Faso (1996–2017): a  
476 systematic review with meta-analysis of epidemiological studies. BMC Public Health. 2018;18(1):551.  
477 doi: 10.1186/s12889-018-5432-7.
- 478 34. Badawi M, Atif M, Mustafa Y. Systematic review and meta-analysis of HIV, HBV and HCV  
479 infection prevalence in Sudan. Virol J. 15, 2018:148.
- 480 35. Hassan-Kadle PP, M. A. Osman MS, Ogurtsov. Epidemiology of viral hepatitis in Somalia:  
481 Systematic review and meta-analysis study. World J Gastroenterol. 2018;24(34):3927. doi:  
482 10.3748/wjg.v24.i34.3927.

- 483 36. Eboumbou Moukoko CE, Ngo Sack F, Essangui Same EG, Mbangue M, Lehman LG. HIV,  
484 HBV, HCV and T. pallidum infections among blood donors and Transfusion-related complications  
485 among recipients at the Laquintinie hospital in Douala, Cameroon. BMC Hematol. 2014 Feb 12;14(1):5.  
486 doi: 10.1186/2052-1839-14-5.
- 487 37. Awili HO, Gitao GC, Muchemi GM. Seroprevalence and Risk Factors for Hepatitis B Virus  
488 Infection in Adolescent Blood Donors within Selected Counties of Western Kenya. Biomed Res Int.  
489 2020; 2020:8578172. Published 2020 Jun 17. doi:10.1155/2020/8578172.
- 490 38. King H, Xing J, Dean HD, Holtzman D. Trends in Prevalence of Protective Levels of Hepatitis B  
491 Surface Antibody Among Adults Aged 18-49 Years With Risk Factors for Hepatitis B Virus Infection-  
492 United States, 2003-2014. Clin Infect Dis. 2020 Apr 15;70(9):1907-1915.doi: 10.1093/cid/ciz537.
- 493 39. Anderson N, Cockcroft A, Shea B. Gender-based violence and HIV: relevance for HIV  
494 prevention in hyperendemic countries of southern Africa. AIDS. 2008;22(suppl 4):S73-S86.
- 495 40. Kouyoumdjian FG, Calzavara LM, Bondy SJ, et al. Intimate partner violence is associated with  
496 incident HIV infection in women in Uganda. AIDS. 2013;27:1331-1338.
- 497 41. Jewkes R, Dunkle K, Nduna M, et al. Intimate partner violence, relationship power inequity, and  
498 incidence of HIV infection in young women in South Africa: a cohort study. Lancet. 2010;376:41-48.
- 499 42. Decker MR, Seage GR, III, Hemenway D, et al. Intimate partner violence functions as both a  
500 risk marker and risk factor for women's HIV infection: findings from Indian husband-wife dyads. J Acquir  
501 Immune Defic Syndr. 2009;51:593-600.
- 502 43. UNAIDS. Democratic Republic of the Congo. Country. 2020 Available online:  
503 <https://www.unaids.org/en/regionscountries/countries/democraticrepublicofthecongo> (accessed on 28  
504 November 2021).
- 505 44. Kashosi TM, Mutendela JK, Mwenebitu D L, Maotela JK, & Mubagwa K. Assissent of virological  
506 quality of transfused blood in the town of Bukavu, South Kivu, Democratic Republic of Congo. The Pan  
507 African medical journal vol. 30 193. July the 4th, 2018; doi:10.11604/pamj.2018.30.193.13457

- 508 45. Salamander Trust, Athena, ONUSIDA, AIDS Legal Network, Projet Empower, HEARD,  
509 Université du KwaZulu-Natal. Action reliant les initiatives sur la violence à l'égard des femmes et le VIH  
510 partout, cadre ALIV(H)E. 2017.
- 511 46. Nduwimana, Françoise. Le droit de survivre: Femmes, violence sexuelle et VIH/SIDA. Droits et  
512 Démocratie= Rights & Democracy, Centre international des droits de la personne et du développement  
513 démocratique= International Centre for Human Rights and Democratic Development, 2004.
- 514 47. UNAIDS, UNESCO, UNFPA, UNHCR and ILO. Evaluation Offices jointly managed an  
515 evaluation of the work of the Joint Programme on preventing and responding to violence against women  
516 and girls (VAWG) in all their diversity 2021 available at <http://www.unaids.org/en/whoweare/evaluation>.
- 517 48. UNAIDS epidemiological estimates, 2021 (<https://aidsinfo.unaids.org/>)
- 518 49. UNAIDSdata2021([https://www.unaids.org/sites/default/files/media.asset/JC3032\\_AIDS](https://www.unaids.org/sites/default/files/media.asset/JC3032_AIDS)  
519 Data\_book\_2021 )
- 520 50. Manguro, Griffins O, et al. "HIV infections among female sex workers in Mombasa, Kenya:  
521 current prevalence and trends over 25 years." International journal of STD & AIDS 31.14. 2020;1389-  
522 1397.
- 523 51. Pettifor AE, van der Straten A, Dunbar MS, Shiboski SC, Padian NS. Early age of first sex: a  
524 risk factor for HIV infection among women in Zimbabwe. AIDS. 2004;18(10):1435-1442
- 525 52. Senn T, Carey M, Vanable P, Coury-Doniger P, Urban M. Characteristics of sexual abuse in  
526 childhood and adolescence influence sexual risk behavior in adulthood. Arch Sex Behav.  
527 2007;36(5):637-64
- 528 53. Fisher JC, Cook PA, Kapiga SH. Alcohol use before sex and HIV risk: situational characteristics  
529 of protected and unprotected encounters among high-risk African women. Sex Transm Dis.  
530 2010;37(9):571-578.
- 531 54. Maganja RK, Maman S, Groves A, Mbwambo JK. Skinning the goat and pulling the load:  
532 transactional sex among youth in Dar es Salaam, Tanzania. AIDS Care. 2007;19(8):974-981

- 533 55. UNDP. Understanding and Acting on Critical Enablers and Development Synergies for Strategic  
534 Investments. New York, NY: United Nations Development Programme; 2012.
- 535 56. Bell TG, Makondo E, Martinson NA, Kramvis A Hepatitis B Virus Infection in Human  
536 Immunodeficiency Virus Infected Southern African Adults: Occult or Overt – That Is the Question. PLoS  
537 ONE. 2012;7(10): e45750. doi:10.1371/journal.pone.0045750.
- 538 57. Modi AA, Feld JJ. Viral hepatitis and HIV in Africa. AIDS Rev. 2007;9:25-39
- 539 58. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:S6-S9
- 540 59. Likhitsup A, Lok AS. Understanding the Natural History of Hepatitis B Virus Infection and the  
541 New Definitions of Cure and the Endpoints of Clinical Trials. Clin. Liver Dis. 2019;23:401-416. doi:  
542 10.1016/j.cld.2019.04.002
- 543 60. Terrault NA, Lok ASF, McMahon BJ, Chang K.-M, Hwang JP, Jonas MM, Brown RS, et al.  
544 Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B  
545 guidance. Hepatology. 2018;67, 1560-1599.
- 546 61. EASL EASL 2017. Clinical Practice Guidelines on the management of hepatitis B virus infection.  
547 J. Hepatol. 2017;67:370-398. doi: 10.1016/j.jhep.2017.03.021.
- 548 62. Stene-Johansen K, Yaqoob N, Overbo J, Aberra H, Desalegn H, Berhe N, et al. Dry Blood  
549 Spots a Reliable Method for Measurement of Hepatitis B Viral Load in Resource-Limited Settings. PLoS  
550 One. 2016 Nov 7;11(11):e0166201. doi: 10.1371/journal.pone.0166201
- 551 63. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50(3):661-  
552 2.10.1002/hep.23190.